Dr. Anshoo Agarwal
Swami Vivekanand Subharti University, Meerut India
Title: Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 tumor marker expressions in neoplastic and non -neoplastic Gall bladder lesions and their clinicopathological correlation
Biography
Biography: Dr. Anshoo Agarwal
Abstract
Gall bladder carcinoma (GBC) corresponds to 1.13 per million in the US. The incidence is high in females and it represent almost three fourths of GBC victims and their highest incidence rate occur in this region, yet only few immunomarker studies are available from this high-predisposing region. GBC has also been reported to show a variable expression pattern among different ethnic groups. GBC results via the dysplasia-metaplasia sequence and the 5-year survival rate for GBC is 32% and for the advanced stage it is only 10%. Current studies have focused on the importance of Cyclin D1, E-cadherin, EGFR, HER- 2, Ki67, and p53 immunomarkers in the development and prognosis of GBC. One of the most genetic aberrations is ascribed to be HER-2 in GBC. HER-2 and other immunomarkers Cyclin D1, E-cadherin, EGFR, Ki67, and p53 can be easily assessed by standard immunohistochemistry methods. However, concrete results have not been obtained due to a limited number of resectable GBC cases presented at the hospitals. We, therefore, attempt to evaluate the immune-expression of these markers in GBC cases and determine their prognostic value in the selected GBC cohort.